<DOC>
	<DOC>NCT02662569</DOC>
	<brief_summary>The primary hypothesis is that both dosing regimens of SC evolocumab (AMG 145) in combination with statin therapy will be well tolerated and will result in greater reduction of LDL-C in diabetic subjects with hyperlipidemia or mixed dyslipidemia.</brief_summary>
	<brief_title>A Double-blind, Randomized Study in Diabetic Subjects With Hyperlipidemia or Mixed Dyslipidemia</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>Males and females with type 2 diabetes (receiving pharmacologic treatment for at least 6 months or longer) with stable diabetes therapy, Lipidlowering therapy must be unchanged for at least 4 weeks or more, Subjects receiving statin therapy at screening must have a fasting LDLC of greater than or equal to 100 mg/dL, Subjects not receiving statin therapy at screening must have a fasting LDLC of greater than or equal to 130 mg/dL. Exclusion criteria: NYHA III or IV heart failure, Uncontrolled cardiac arrhythmia, Uncontrolled hypertension, Type 1 diabetes or poorly controlled type 2 diabetes, Uncontrolled hypothyroidism or hyperthyroidism.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>